Cargando…
Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
Psoriatic arthritis (PsA) is a heterogeneous disease that may develop in up to 30% of patients with psoriasis. PsA mainly involves peripheral joints; however, axial skeleton and entheses can also be involved. PsA is the result of a complex interplay between an individual’s genotype and environmental...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioExcel Publishing Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166261/ https://www.ncbi.nlm.nih.gov/pubmed/37168876 http://dx.doi.org/10.7573/dic.2023-2-7 |